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Table 1. Unadjusted Associations of Transplant Characteris-
tics with Days Alive and Out of Hospital
Median Coefficient
N (IQR*) (95% CI) p-value†Age 0.16
1-19 26 43 (19-57) 0 (reference)
20-34 20 52 (23-75) 9.1 (-7.7, 25.8)
35-49 20 67 (36 – 77) 15.2 (-1.5, 31.9)
50-73 18 72 (15 -86) 18.2 (0.9, 35.4)
Institution 0.03
UW Medical Center 57 66 (28 – 79) 0
Seattle Children’s
Hospital27 40 (19 – 57) -14.9 (-28.1, -1.7)Sex 0.21
Female 42 61 (28 – 76) 0
Male 42 53 (12 – 73) -8.1 (-20.6, 4.4
Race 0.002
Caucasian 49 66 (38 – 77) 0
Non-Caucasian 35 38 (14 – 60) -19.5 (-31.6, -7.4)
Disease-Risk 0.02
Standard 74 59 (29 – 76) 0
High 10 15 (0 – 57) -22.7 (-41.6, -3.8)
CMV seropositivity 0.05
Neg 31 66 (40 – 77) 0
Pos 53 46 (14 – 73) -12.9 (-25.7, -0.1)
Comorbidity score
(in adults)0.590, 1 14 50 (34 – 64) 0
2 19 73 (38 – 79) 11.8 (-8.8, 32.4)
3 14 50 (27 – 66) -1.1 (-23.3, 21.0)
4 – 8 15 66 (15 – 83) 5.3 (-16.5, 27.0)
Conditioning
regimen0.34CY / Flu / TBI 65 59 (20 – 76) 0
Treo / Flu / TBI 19 46 (14 – 68) -7.3 (-22.4, 7.7)
TBI dose (cGy) 0.46
200 – 300 32 59 (21 – 81) 0
1320 52 54 (20 – 71) -4.9 (-17.9, 8.0)
Number of donors 0.39
1 9 38 (14 – 54) -10.9 (-31.1, 9.4)
2 71 59 (27 – 77) 0
3 4 29 (14 – 58) -14.8 (-44.2, 14.7)*IQR 5 inter-quartile range, 25th to 75th percentiles of distribution
†Test for homogeneity across factor levels207
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Introduction: Low bone mineral density (BMD) is an important
multifactorial cause of morbidity in patients with b-thalassemia.
With recent therapeutic advances such as hematopoietic stem cell
transplantation (HSCT), thalassemic patients can live longer but os-
teoporosis is now a major health concern.
Method: In this study, we evaluated the changes of bone density in
46 patients with b thalassemia major who were candidates for HSCT
before and after transplantation. The average age of patients was 13.4
years (range 3-29 years). Twenty four patients (52.2%) were male.
All patients underwent HSCT from HLA-identical related donors.
Nine patients (19.6%) co-transplanted with mesenchymal cells.
Dual-energy X-ray absorptiometry (DXA) was performed on lumbar
vertebrae and femoral neck in all patients before starting pre-
transplant regimens and repeated at one year after transplantation.
Results: Low BMD was found in 7 patients (15.2%) before trans-
plantation and in 18 patients (39.1%) one year after transplantation.BMD changes in femoral neck and lumbar area were significant at
one year after transplant (p\0.001) while no significant changes
were found in the whole femur (p 5 0.22). Female gender (p 5
0.005) and low body mass index (p 5 0.05) were correlated with
low BMD and defined as independent risk factors for low BMD at
one year after transplantation. There was no significant difference
inBMDchanges betweenpatientswith andwithout co-transplantation
of mesenchymal cells.
Conclusion:Due to decrease in BMDafterHSCT, it is suggested to
manage low BMD before transplantation. Longer follow-up will
help to better clarify the role of HSCT in BMD changes of thalasse-
mic patients; moreover, further studies are suggested to evaluate the
role of co-transplantation of HCT together with mesenchymal cells
on BMD improvement of thalassemic patients.208
MEDICATION ERRORS AMONG PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS IN AN OUTPATIENT CLINIC
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As care of hematopoietic stem cell transplant (HSCT) patients is
increasingly provided in the ambulatory setting a significant amount
of responsibility is also switched to family members. The goal of this
project was to identify the incidence and source of medication errors
in a complex outpatient population and to develop system changes to
increase safety and reliability of home administration of medications.
Between 05/11 and 08/11, a prospective study was conducted on
pediatric HSCT recipients managed in a hospital-based outpatient
clinic. Patients within one year post-transplant or later if still on im-
munosuppressive therapy were included. Medication reconciliation
was performed by a clinic nurse every visit and verified by one of
two advanced nurse practitioners (ANP). The latter compared the
information with dictated clinic notes to confirm accuracy of medi-
cation administration. For variance the ANP determined the source
of error and clinical consequence, if any. The results were conferred
with the transplant physician for change of management.
Medications were classified as immunosuppressives (IS), anti-
infectives (AI) and others (OT). 300 visits (285 allogeneic HSCT-
and 15 autologous HSCT) occurred among 49 patients during the
4-month period. 19 medication errors were identified (6% inci-
dence) among 10 patients. 5 patients experienced multiple episodes
of error. All were administration errors. 18 errors (95%) occurred
at home and one (5%) in the clinic. 18 errors were found in alloge-
neic patients, 1 in an autologous patient. 7 errors (37%) involved
IS, 7 (37%) involved AI, and 5 (26%) fromOT.Themedian time be-
fore an error was detected was 2 (range 1-24) days. Themedian num-
ber of drugs taken by each patient was 6 (range 3-14). The nature of
the errors was wrong dose (too high 42%, too low 21%) and omis-
sion of a dose (7%). The source of the error was traced to miscom-
munication in 16 events (verbal 16%, written 68%), prescriber error
once (5%), and failure of caregiver to refill medication twice (11%).
No patient demonstrated significant clinical side-effects from medi-
cation errors. Many medications given post HSCT have a narrow
therapeutic window. Family members must take responsibility for
many skills quickly post HSCT. Standardized dosing strategies
and improved communication between the caregivers and healthcare
providers may decrease error rate and improve medication adher-
ence and safety of the care delivered.209
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Children treated with hematopoietic stem cell transplantation
(HSCT) are at particular risk to develop disturbances in dental
